So, the UK public have delivered their verdict and Theresa May is set to continue as Prime Minister and is forming a Government with “confidence and supply” from of the Democratic Unionist Party (DUP).

You can read more about how the new parliament might affect the life sciences sector, including what the DUP has to say in its manifesto in our blog ‘What does the outcome of the 2017 General Election mean for the UK life sciences sector?’.

I will also touch on what the emerging government agenda means for our sector and Brexit at our next monthly webinar this Thursday at 16:00, do register here for the latest or to ask a question.

The priority for our sector is getting the highly complex and technical issues associated with Brexit right and the BIA will continue to make our members’ expertise available to ministers and officials in the coming weeks and months. Early agreement on key issues like the regulation of medicines, the regime to enable non-UK nationals to work and contribute to the UK life science ecosystem, trade, finance support, market and intellectual property rules, would be the best way to ensure speedy and continuing global inward investment into the UK and EU. It would also be in the best interest of patients who require access to innovative healthcare.

Even if what the election means for Brexit is not yet clear, what both main parties were clear on is the campaign on the desire to turn the UK into the most innovative country in the world as highlighted in our recent blog. Our sector is key to taking the UK’s outstanding science base and translating it into economic jobs and growth. Measures to support this goal should attract broad support in the new Parliament.

We will be pushing this at our annual Parliament Day (taking place on 6 July) where CEOs can meet with new and returning MPs, Peers, Ministers and civil servants. The event will be followed by our Summer Reception at the IET Savoy Place which will be the perfect opportunity to network with fellow industry colleagues over a drink. You can register your place here.

Aside from the election, last week saw the ASCO General Meeting 2017 which was held in Chicago. One of the biggest stories to come out of the meeting was around the high cost of cancer drugs, with US doctors raising concerns. On a more positive note, British researchers (The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust) used the event to announce the results of their trial of a new drug for ovarian cancer, a disease for which treatment options are currently extremely limited. You can read more ASCO 2017 news here.

Next week, we will be in in San Diego for BIO 2017, if you missed our webinar on what to expect it is available to view on YouTube here – I look forward to catching up with many of you on the West Coast next week.